NVS
Novartis AG ADR
$159.9+3.74%
Setup
Watch
Buy Zone
$162.5-$170.63
Sector
Drug Manufacturers - General
Industry
Drug Manufacturers - General
39
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
NVS chart
Loading chart…
Overall Quality39
RS Rating
62
relative strength
Fundamentals
60
Solid fund-Q
Volume Demand
82
-8% vs avg
Technical Setup
75
6/8 checks
Industry/Theme
91
Drug Manufacturers - General
Trade Plan
Avoid
Entry
$162.5
Entry Zone
$162.5-$170.63
Stop / Risk
$149.5
RS Rating
62
Volume confirmed
Yes
Targets
$195 / $203.13
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $162.5–$170.63Stop $149.5Target $195 / $203.13
Market regimeRange
Quality39
RS Rating62
Above 50-MA+7.01%
Above 200-MA+11.44%
VolumeConfirmed
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
39
MarketRange
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q60 · Solid
StatusAvoid
Stock Data
52-Week Range112 – 170
Price % Chg YTD15.98%
Price % Chg 4wk11.44%
50-Day Avg Vol1.7 Mil
P/E Ratio22.1
Market Cap$284B
SectorHealthcare
IndustryDrug Manufacturers - General
Company Fundamentals
EPS % Chg (Qtr)-9.32%
Sales % Chg (Qtr)-0.59%
EPS Growth 5y15.38%
Sales Growth 5y2.41%
Annual ROE35.38%
Gross Margin74.58%
Operating Margin29.69%
Net Margin24.89%
Debt / Equity1.22
Setup levels
Current price
$159.9
Pivot
$162.5
Distance to buy
-6.2%
52-week range
112.34-170.47
Trigger evidence
No active trigger evidence available.
Pattern levels: near highs
Financial health checks
2/5
Return on equity above 15%
ROE 35.38%
Net margin above 10%
Net margin 24.89%
EPS growing quarter on quarter
EPS q/q -9.32%
Sales growing quarter on quarter
Sales q/q -0.59%
Debt to equity below 1.0
D/E 1.22
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE35.38%
vs sector +12.4%
Net margin24.89%
vs sector +5.6%
Gross margin74.58%
vs sector +2.9%
EPS growth q/q-9.32%
vs sector -28.5%
Sales growth q/q-0.59%
vs sector -21.8%
Debt / equity1.22
vs sector +0.50
Business quality
60
GradeSolid
EPS rating33
P/E22.1
Market cap$284B
IndustryDrug Manufacturers - General
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-06-25
Trigger date
—
Days on list
9
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.